Chronic Heart Failure (CHF) encompasses heterogeneous groups of patients with a wide spectrum of symptoms and different causes. The CHMP Guideline on the clinical investigations of medicinal products for the treatment of cardiac failure (CPMP/EWP/235/95) addresses the development issues in this specific patient population.
|Download document||Concept paper on the need for revision of note for guidance on clinical investigation of medicinal products for the treatment of cardiac failure|
|Status||draft: consultation open|
|Consultation start date||01/03/2013|
|Consultation end date||31/05/2013|
|Email address for email@example.com|